1.China Medical University-The Queen’s University of Belfast Joint College,110122 Shenyang,China; 2.College of Animal Science and Technology,Jilin Agricultural University,130118 Changchun,China
Abstract:Ebola virus disease is a fulminating infectious disease caused by the Ebola virus infection and result in Humans and primates with a fever, bleeding and diarrhea as the main clinical characteristics, and the disease case fatality rate is as high as 90%. It was found in the first time in 1976 in Zaire and Sudan of Africa and has caused many large-scale outbreak in Africa to date. In recent years, the disease has spread to areas outside the African continent, and it has occurred in the United States, Spain, UK and Italy, which caused the wide attention from all over the world. In order to effectively prevent and control the ebola virus disease, this article was summarized from the etiology, epidemiology, clinical symptoms, pathological changes, as well as prevention and control, and so on.
徐鹤峰, 胡桂学. 埃博拉病毒病概述[J]. 中国人兽共患病学报, 2020, 36(10): 864-872.
XU He-feng, HU Gui-xue. An overview of Ebola virus disease. Chinese Journal of Zoonoses, 2020, 36(10): 864-872.
[1] Li YH,Chen SP.Evolutionary history of Ebola virus[J].Epidemiol Infect,2014,142(6): 1138-1145.DOI:10.1017/ S0950268813002215 [2] WHO.Ebola haemorrhagic fever in Zaire,1976.[J].Bull World Health Organ,1978,56(2): 271-293. [3] Centers for Disease Control and Prevention.Ebola (Ebola virus disease: 2014 West Africa outbreak[EB/OL].[2020-03-03]. http: / /www.cdc.gov /vhf /ebola.2014 [4] WHO. Ebola virus disease [EB/OL].[2019-12-17]. https://www.who.int/zh/news-room/fact-sheets /detail/ ebola-virus-disease [5] WHO.WHO statement on the meeting of the International Nealth Regulations Emergency Commitlee concerning the international spread of wild polioviros[EB/OL][2014-05-05].http: / /www.who.int /mediacentre /news /statements /2014/polio-20140505/en/ [6] Zawilińska B,Kosz-Vnenchak M.General introduction into the Ebola virus biology and disease[J].Folia Med Cracov,2014,54(3):57-65.DOI: 10.1016/0168-1702(95)00080-1 [7] Kiley MP, Bowen ET, Eddy GA, et al.Filoviridae: a taxonomic home for Marburg and Ebola viruses[J]. Intervirology, 1982, 18(1/2): 24-32. DOI:10.1159/000149300 [8] Negredo A, Palacios G, Vázquez-Morón S, et al.Discovery of an ebolavirus-like filovirus in Europe[J]. PLoS Pathog, 2011,7(10):e1002304. DOI:10.1371/journal.ppat.1002304 [9] Geisbert TW,Jahrling PB.Differentiation of filoviruses by electron microscopy[J].Virus Res,1995, 39(2/3) : 129-150.DOI: 10.1016/0168-1702(95)00080-1 [10] Zaki SR,Goldsmith CS.Pathologic features of filovirus infections in humans[J].Curr Top Microbiol Immunol,1999,235: 97-116.DOI: 10.1007/978-3-642-59949-1-7 [11] Feldmann H.Ebola-a growing threat[J].N Engl J Med,2014,371: 1375-1378.DOI: 10.1056/NEJMp1405314 [12] Noda T, Hagiwara K, Sagara H, et al.Characterization of the Ebola virus nucleoprotein-RNA complex[J].J Gen Virol,2010,91(Pt 6):1478-1483.DOI: 10.1099/vir.0.019794-0 [13] Cantoni D,Rossman JS.Ebola viruses: New roles for old proteins[J].PLoS Negl Trop Dis,2018,12(5) : e0006349.DOI: 10.1371/journal.pntd.0006349 [14] Dziubanska PJ,Derewenda U,Ellena JF,et al.The structure of the C-terminal domain of the Zaire ebolavirus nucleoprotein[J].Acta Crystallogr D Biol Crystallogr,2014,70(Pt9) : 2420-2429.DOI: 10.1107/S1399004714014710 [15] Reid SP,Leung LW,Hartman AL,et al.Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation[J].J Virol,2006,80(11):5156-5167.DOI: 10.1128/JVI.02349-05 [16] Basler CF,Wang X,Muhlberger E,et al.The Ebola virus VP35 protein functions as a type I IFN antagonist[J]. Proc Natl Acad Sci USA,2000,97(22 ) :12289-12294.DOI: 10.1073/pnas.220398297 [17] Modrof J,Becker S,Muhlberger E.Ebola virus transcription ac-tivator VP30 is a zinc-binding protein[J].J Virol,2003,77(5) : 3334-3338.DOI: 10.1128/JVI.77.5.3334-3338.2003 [18] Walsh PD,Abernethy KA,Bermejo M,et al.Catastrophic ape decline in western equatorial Africa[J].Nature,2003,422(6932):611-614.DOI: 10.1038/nature01566 [19] Carroll SA,Towner JS,Sealy TK,et al.Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences[J].J Virol,2013,87(5) :2608-2616.DOI: 10.1128/JVI.03118-12 [20] Towner JS,Sealy TK,Khristova ML,et al.Newly discovered Ebola virus associated with hemorrhagic feveroutbreak in Uganda[J].PLoS Pathog,2008,4(11) : e1000212.DOI: 10.1371/journal.ppat.1000212 [21] Bowen ET,Lloyd G,Harris WJ,et al.Viral haemorrhagic fever in southern Sudan and northern Zaire.Preliminary studies on the aetiological agent[J].Lancet,1977,1(8011) : 571-573.DOI: 10.1016/s0140-6736(77)92001-3 [22] Le GB,Formenty P,Wyers M,et al.Isolation and partial characterisation of a new strain of Ebola virus[J].Lancet,1995,345(8960):1271-1274.DOI: 10.1016/s0140-6736(95)90925-7 [23] Jahrling PB,Geisbert TW,Dalgard DW,et al.Preliminary report: isolation of Ebola virus from monkeys imported to USA[J].Lancet,1990,335(8688):502-505.DOI: 10.1016/0140-6736(90)90737-p [24] Barrette RW,Xu LZ,Rowland JM,et al.Current perspectives on the phylogeny of Filoviridae[J].Infect Genet Evol,2011,11(7) : 1514-1519.DOI: 10.1016/j.meegid.2011.06.017 [25] Baize S,Pannetier D,Oestereich L,et al.Emergence of Zaire Ebola virus disease in Guinea[J].N Engl J Med,2014,371(15) : 1418-1425.DOI: 10.1056/NEJMoa1404505 [26] Gupta M,MacNeil A,Reed ZD,et al.Serology and cytokine profiles in patients infected with the newly discovered Bundibugyo ebolavirus[J].Virology,2012,423(2) :119-124.DOI: 10.1016/j.virol.2011.11.027 [27] Barrette RW,Metwally SA,Rowland JM,et al.Discovery of swine as a host for the Reston ebola virus[J].Science,2009,325: 204-206.DOI: 10.1126/science.1172705 [28] Pan YY,Zhang W,Cui L,et al.Reston virus in domestic pigs in China[J].Arch Virol,2014,159(5):1129-1132.DOI:10.1007/s00705-012-1477-6 [29] Piercy TJ,Smither SJ,Steward JA,et al.The survival of filoviruses in liquids,on solid substrates and in a dynamic aerosol[J].J Appl Microbiol,2010,109(5):1531-1539.DOI: 10.1111/j.1365-2672.2010.04778.x [30] WHO. Ebola hamorrhagic fever in Sudan,1976. Report of a WHO/international study team[J]. Bull World Health Organ,1978, 56(2): 247-270. [31] Groseth A,Feldmann H,Strong JE.The ecology of Ebola virus[J].Trends Microbiol,2007,15(9): 408-416.DOI: 10.1016/j.tim.2007.08.001 [32] Monath TP.Ecology of Marburg and Ebola viruses: speculations and directions for future research[J].J Infect Dis,1999,179(Suppl 1): 127-138.DOI: 10.1086/514281 [33] Leroy EM, Kumulungui B,Pourrut X,et al.Fruit bats as reservoirs of Ebola virus[J]. Nature,2005,438(7068): 575-576.DOI: 10.1038/438575a [34] Hayman DT, Emmerich P, Yu M, et al.Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses[J]. PLoS ONE,2010,5(8):e11978.DOI: 10.1371/journal.pone.0011978 [35] Bausch DG,Schwarz L.Outbreak of Ebola virus disease in Guinea: where ecology meets economy[J]. PLoS Negl Trop Dis,2014,8(7):e3056.DOI: 10.1371/journal.pntd.0003056 [36] Strong JE,Wong G,Jones SE,et al.Stimulation of Ebola virus production from persistent infection through activation of the Ras /MAPK pathway[J].Proc Natl Acad Sci USA,2008,105(46):17982-17987.DOI: 10.1073/pnas.0809698105 [37] Morvan JM,Deubel V,Gounon P,et al.Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic[J].Microbes Infect,1999,1(14) : 1193-1201.DOI: 10.1016/s1286-4579(99)00242-7 [38] Gallaher WR.Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses[J].Cell,1996,85(4):477-478.DOI: 10.1016/s0092-8674(00)81248-9 [39] Weingartl HM,Nfon C,Kobinger G.Review of Ebola virus infections in domestic animals[J].Dev Biol,2013,135: 211-218.DOI: 10.1159/000178495 [40] Nkoghe D,Formenty P,Leroy EM,et al.Multiple Ebola virus haemorrhagic fever outbreaks in Gabon,from October 2001 to April 2002[J].Bull Soc Pathol Exot,2005,98(3):224-229. [41] Bausch DG,Towner JS,Dowell SF,et al.Assessment of the risk of Ebola virustransmission from bodily fluids and fomites[J].J Infect Dis,2007,196(Suppl 2) : S142-S147.DOI: 10.1086/520545 [42] World Health Organiztion (WHO). Ebola virus disease [EB/OL].[2015-01-26].http://www.who.int/mediacentre/factsheets/fs103/zh/ [43] Rollin PE,Williams RJ,Bressler DS,et al.Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States[J].J Infect Dis,1999,179(Suppl 1):S108-114.DOI: 10.1086/514303 [44] Leroy EM,Epelboin A,Mondonge V,et al.Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo,Democratic Republic of Congo,2007[J].Vector Borne Zoonotic Dis,2009,9(6):723-728.DOI: 10.1089/vbz.2008.0167 [45] World Health Organization.Ebola virus disease [EB/OL].[2014-04-1] [2014-08-14].http://www.who.int/mediacentre/factsheets/fs103/en/. [46] Du Toit A.Ebola virus in west Africa[J].Nat Rev Microbiol,2014,12(5):312. DOI: 10.1038/nrmicro3267 [47] Akinfeyeva LA,Aksyonova OI,Vasilyevich IV,et al.A case of Ebola hemorrhagic fever[J].Infektsionnye Bolezni,2005,3(1):85-88.DOI: 10.3981/j.issn.1000-7857.2014.24.001 [48] Miranda ME,White ME,Dayrit MM,et al.Seroepidemiological study of filovirus related to Ebola in the Philippines[J].Lancet,1991,337(8738):425-426.DOI: 10.1016/0140-6736(91)91199-5 [49] Centres for disease control and prevention. Ebola hemorrhagic fever signs and symptoms [EB/OL]. [2014-08-15]. http://www.cdc.gov/vhf/ebola/symptoms/index.html. [50] World Health Organization: Ebola haemorrhagic fever: fact sheet revised inMay 2004[J].Wkly Epidemiol Rec,2004,79(49) : 435-439. [51] Khan AS, Tshioko FK, Heymann DL, et al.The reemergence of Ebola haemorrhagic fever, Democratic Republic of the Congo, 1995[J]. J Infect Dis, 1999, 179(Suppl 1): 76-86. DOI: 10.1086/514306 [52] Heinz F, Thomas WG.Ebola haemorrhagic fever[J]. The Lancet, 2011, 377: 849-862. DOI: 10.1016/S0140-6736(10)60667-8 [53] Chowell G,Nishiura H.Characterizing the transmission dynamics and control of ebola virus disease[J].PLoS Biol,2015,13(1):e1002057.DOI: 10.1371/journal.pbio.1002057 [54] Singh G, Kumar A, Singh K, et al.Ebola virus: an introduction and its pathology[J]. Rev Med Virol, 2016,26: 49-56. DOI:10.1002/rmv.1863 [55] Mahanty S,Bray M.Pathogenesis of filoviral haemorrhagic fevers[J].Lancet Infect Dis,2004,4(8):487-498.DOI: 10.1016/S1473-3099(04)01103-X [56] Geisbert TW, Pushko P, Anderson K, et al.Evaluation in nonhuman primates of vaccines against Ebola virus[J]. Emerg Infect Dis, 2002, 8(5): 503-507. DOI: 10.3201/eid0805.010284 [57] Gross L, Lhomme E, Pasin C, et al.Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta analysis of determinants of antibody response variability after vaccination[J]. Int J Infect Dis, 2018 (74): 83-96. DOI: 10.1016/j.ijid.2018.06.022 [58] Porter KR,Raviprakash K.DNA vaccine delivery and improved immunogenicity[J]. Curr Issues Mol Biol,2017,22:129-138. DOI: 10.21775/cimb.022.129 [59] Uhlig KM,Schülke S,Scheuplein VA,et al. Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen specific cytotoxic T cell response [J]. J Virol,2015,89(17)9044-9060. DOI:10.1128/JVI.00844-15 [60] Coufalova D,Remnant L,Hernychova L,et al.An inter-subunit protein-peptide interface that stabilizes the specific activity and oligomerization of the AAA+ chaperone Reptin[J]. J Proteomics,2019,199:89-101. DOI: 10.1016/j.jprot.2019.02.012 [61] Hasan M,Ghosh PP,Azim KF,et al.Reverse vaccinology approach to design a novel multi-epitope subunit vaccine against avian influenza A(H7N9)virus[J]. Microb Pathog,2019,130:19-37. DOI: 10.1016/j.micpath.2019.02.023 [62] Garbutt M, Liebscher R, Wahl-JensenV, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses[J]. J Virol, 2004, 78(10): 5458-5465. DOI: 10.1128/JVI.78.10.5458-5465.2004 [63] Marzi A, Mire CE.Current Ebola virus vaccine progress[J]. BioDrugs, 2019, 33(1): 9-14. DOI: 10.1007/s40259-018-0329-7 [64] Kennedy SB, Bolay F, Kieh M, et al.Phase 2 placebo-controlled trial of two vaccines to prevent ebola in Liberia[J]. N Engl J Med, 2017, 377(15): 1438-1447. DOI:10.1056/NEJMoa1614067 [65] Henao-Restrepo AM, Longini IM, Egger M, et al.Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomisedtrial[J]. Lancet, 2015, 386(9996): 857-866. DOI: 10.1016/S0140-6736(15)61117-5 [66] Henao-Restrepo AM, Camacho A, Longini IM, et al.Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label,cluster-randomised trial[J]. Lancet, 2017, 389(10068): 505-518. DOI: 10.1016/S0140-6736(16)32621-6 [67] Gsell PS, Camacho A, Kucharski AJ, et al.Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report[J]. Lancet Infect Dis, 2017, 17(12): 1276-1284. DOI: 10.1016/S1473-3099(17)30541-8 [68] Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al.Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and-Ad5-vectored Ebola vaccine: An open phaseⅠ/Ⅱtrial in healthy adults in Russia[J]. Hum Vaccin Immunother, 2017, 13(3): 613-620. DOI: 10.1080/21645515.2016.1238535 [69] Zhu FC, Hou LH, Li JX, et al.Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet, 2015, 385(9984): 2272-2279. DOI:10.1016/S0140-6736(15)60553-0 [70] Li JX, Hou LH, Meng FY, et al.Immunity duration of a recombinant adenovirus type-5vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet Glob Health, 2017, 5(3): e324-e334. DOI: 10.1016/S2214-109X(16)30367-9 [71] Geisbert TW, Lee AC, Robbins M, et al.Postexposure Protection of non-human primates against a lethal ebola virus challenge with RNA interference: aproof-of-concept study[J]. Lancet, 2010, 375(9279):1896-1905. DOI: 10.1016/S0140-6736(10)60357-1 [72] Qiu X, Wong G, Audet J, et al.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp[J]. Nature, 2014, 514(7520): 47-53. DOI:10.1038/nature13777 [73] Pettitt J, Zeitlin L, Kim DH, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail [J]. Sci Transl Med, 2013, 5, 199 ra 113. DOI:10.1126/scitranslmed.3006608 [74] Geisbert TW.Medical research: Ebola therapy protects severely ill monkeys[J]. Nature, 2014, 514(7520): 41-53. DOI:10.1038/nature13746